Theravance Biopharma (NASDAQ:TBPH) Stock Price Passes Above 50-Day Moving Average – What’s Next?

Theravance Biopharma, Inc. (NASDAQ:TBPH) shares crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $18.96 and traded as high as $20.02. Theravance Biopharma shares last traded at $19.82, with a volume of 263,756 shares.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on TBPH shares. Wall Street Zen cut Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. Oppenheimer assumed coverage on shares of Theravance Biopharma in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price target on the stock. BTIG Research raised their price objective on shares of Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, November 26th. Finally, HC Wainwright lifted their price objective on Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $27.80.

Theravance Biopharma Price Performance

The company has a market capitalization of $1.00 billion, a PE ratio of 34.77 and a beta of 0.14. The stock has a 50-day simple moving average of $18.96 and a 200 day simple moving average of $15.53.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.10. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%.The business had revenue of $19.99 million during the quarter, compared to the consensus estimate of $19.89 million. As a group, research analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total value of $582,506.25. Following the sale, the senior vice president owned 277,695 shares of the company’s stock, valued at $5,206,781.25. This represents a 10.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 6.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Theravance Biopharma by 2.5% during the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock valued at $32,289,000 after acquiring an additional 54,152 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Theravance Biopharma by 0.4% during the second quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company’s stock worth $9,863,000 after buying an additional 3,416 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Theravance Biopharma by 6.2% during the third quarter. Dimensional Fund Advisors LP now owns 766,704 shares of the biopharmaceutical company’s stock valued at $11,193,000 after buying an additional 44,634 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in Theravance Biopharma during the third quarter worth approximately $10,611,000. Finally, Bank of America Corp DE raised its holdings in Theravance Biopharma by 16.5% in the 2nd quarter. Bank of America Corp DE now owns 539,645 shares of the biopharmaceutical company’s stock valued at $5,952,000 after acquiring an additional 76,417 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.